Literature DB >> 8240348

Resistance to methotrexate is associated with selective changes of alpha 2,6- and alpha 2,3-sialyltransferase activities toward N-acetyllactosaminic sequences in human colon cancer cell line HT-29.

F Dall'Olio1, N Malagolini, S Guerrini, F Serafini-Cessi.   

Abstract

In previous works we established that the alpha 2,6-sialyltransferase acting on N-acetyllactosaminic sequences [alpha 2,6(N)ST, E.C. 2.4.99.1] behaves, in colonic cells, as an oncodevelopmentally regulated enzyme. Subpopulations of the human colon cancer cell line HT-29 adapted to grow in 10(-5) M methotrexate (MTX), permanently retain the ability to differentiate as mucus-secreting cells when kept confluent for extended periods of time [Lesuffleur et al. (1991) J. Cell Biol. 115, 1409-1418]. In this study we have compared the activities of five sialyltransferases acting on N- or O-linked chains of glycoproteins in parental HT-29 and in the 10(-5) M MTX-resistant variant. Both cell lines were studied during the exponential phase of growth as well as after a long period of postconfluent culture (28-30 days). Regardless the culture conditions, resistance to 10(-5) M MTX is associated with a virtual disappearance of alpha 2,6(N)ST activity. This change results in a dramatic reduction of the reactivity of cell membranes with the fluorescent lectin from Sambucus nigra, specific for alpha 2,6-sialylated structures. The activity of the alpha 2,3-sialyltransferase which acts on N-acetyllactosaminic sequences increases about two times in postconfluent cultures of 10(-5) M MTX-resistant cells, suggesting a close relationship with the differentiation degree. No significative changes were observed in the activity of other sialyltransferases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240348     DOI: 10.1006/bbrc.1993.2308

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Differentiation -dependent expression of human beta-galactoside alpha 2,6-sialyltransferase mRNA in colon carcinoma CaCo-2 cells.

Authors:  F Dall'Olio; N Malagolini; S Guerrini; J T Lau; F Serafini-Cessi
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

2.  Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation.

Authors:  P Delannoy; I Kim; N Emery; C De Bolos; A Verbert; P Degand; G Huet
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion.

Authors:  S Hennebicq-Reig; T Lesuffleur; C Capon; C De Bolos; I Kim; O Moreau; C Richet; B Hémon; M A Recchi; E Maës; J P Aubert; F X Real; A Zweibaum; P Delannoy; P Degand; G Huet
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

4.  N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma.

Authors:  Takeaki Kudo; Hiroaki Nakagawa; Masato Takahashi; Jun Hamaguchi; Naoya Kamiyama; Hideki Yokoo; Kazuaki Nakanishi; Takahito Nakagawa; Toshiya Kamiyama; Kisaburo Deguchi; Shin-Ichiro Nishimura; Satoru Todo
Journal:  Mol Cancer       Date:  2007-05-09       Impact factor: 27.401

5.  GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells.

Authors:  G Huet; S Hennebicq-Reig; C de Bolos; F Ulloa; T Lesuffleur; A Barbat; V Carrière; I Kim; F X Real; P Delannoy; A Zweibaum
Journal:  J Cell Biol       Date:  1998-06-15       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.